FDA-approved
Hormones & metabolism
Albiglutide
Evidence
FDA approved
Class
GLP-1 receptor agonist fused to albumin
KEY TAKEAWAY
Albiglutide is a GLP-1 receptor agonist fused to human albumin so it lasts about a week. It was sold as Tanzeum. The FDA approved albiglutide (Tanzeum) in 2014. The manufacturer stopped selling it in 2018 for commercial reasons.
Written by the Veylo editorial team · Updated
November 2026
What it is
GLP-1 receptor agonist fused to albumin
Approved for
Type 2 diabetes
Key fact
The FDA approved albiglutide (Tanzeum) in 2014. The manufacturer stopped selling it in 2018 for commercial reasons.
Route
Weekly subcutaneous injection
Evidence strength
FDA approved
Albiglutide is a GLP-1 receptor agonist fused to human albumin so it lasts about a week. It was sold as Tanzeum.
It activates GLP-1 receptors, which raises insulin release when blood sugar is high and slows stomach emptying.
The FDA approved albiglutide (Tanzeum) in 2014. The manufacturer stopped selling it in 2018 for commercial reasons.
Type 2 diabetes.
Nausea, diarrhea and injection-site reactions were common. The label carried a boxed warning about thyroid C-cell tumors seen in rodents.
U.S. FDA prescribing information for Albiglutide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.